1 Definition and scope
Biomarkers are measurable indicators of a biological state, process, or condition. They may be derived from blood, urine, tissue, imaging studies, or other bodily materials, and they are used to detect normal function, disease processes, or responses to interventions. In practice, biomarkers help translate complex biology into observable evidence that can be compared, quantified, and tracked over time.
The term is broad and includes both simple laboratory measurements and more complex patterns from molecular, biochemical, or imaging data. Biomarkers are used in clinical care, biomedical research, and drug development because they can provide information that is often more objective and repeatable than direct observation alone.
1.1 Core concept
A biomarker is any objectively measured characteristic that reflects a biological process or condition. This may include a substance in the body, a pattern in a scan, or a molecular signature associated with a disease. The key feature is measurability: a biomarker must be detectable in a standardized way so that results can be compared across patients, experiments, or time points.
Biomarkers can indicate disease presence, risk, severity, progression, or response to therapy. Some are closely tied to a specific disorder, while others are more general indicators of inflammation, injury, or metabolic change.
1.2 Distinction from symptoms and signs
Symptoms are subjective experiences reported by a person, such as pain or fatigue, while signs are observable findings identified by a clinician, such as a rash or fever. Biomarkers differ from both because they are defined by measurable biological evidence rather than personal experience or bedside observation.
A clinical sign may be supported by a biomarker, and a symptom may prompt biomarker testing, but the categories are not identical. For example, elevated blood glucose is a biomarker, while thirst is a symptom. This distinction is important in diagnosis, research, and trial design, where objective measures are often needed.
1.3 Historical development
The idea of using measurable bodily features in medicine is longstanding, beginning with basic measurements such as pulse, temperature, and urine appearance. As laboratory medicine advanced, chemical assays made it possible to quantify substances in blood and other fluids, expanding the role of objective testing in diagnosis.
In the late 20th and early 21st centuries, molecular biology, genomics, proteomics, and imaging technologies greatly broadened the field. Biomarkers became central to personalized medicine, targeted treatment, and clinical trials, where they are used not only to describe disease but also to guide decisions and evaluate outcomes.
2 Types of biomarkers
Biomarkers are classified according to the role they play in medicine or research. A single biomarker may fit more than one category depending on context, and some markers are useful for both diagnosis and monitoring. The classification mainly reflects how the measurement is interpreted.
2.1 Diagnostic biomarkers
Diagnostic biomarkers help identify the presence of a disease or condition. They are used to distinguish affected individuals from those who are not affected, often by detecting a specific molecule, pattern, or physiological abnormality.
These biomarkers are valuable when a disorder has nonspecific clinical features or when early confirmation is needed. Examples include markers used to detect infection, autoimmune activity, or organ injury.
2.2 Prognostic biomarkers
Prognostic biomarkers provide information about the likely course of a condition independent of treatment. They may indicate whether a disease is likely to progress slowly or aggressively, or whether a patient has a higher or lower chance of recurrence or complications.
Such markers are useful in counseling, risk stratification, and study design. They help clinicians estimate future outcomes based on measurable biological features present at an earlier stage.
2.3 Predictive biomarkers
Predictive biomarkers indicate the likelihood that a person will respond to a particular treatment. Unlike prognostic biomarkers, which relate to outcome in general, predictive markers are tied to therapeutic effect.
They are especially important in targeted therapy, where a specific biological feature suggests that one treatment may be more effective than another. Predictive biomarkers support treatment selection and may reduce exposure to ineffective therapies.
2.4 Pharmacodynamic biomarkers
Pharmacodynamic biomarkers show that a biological response has occurred after a drug or intervention is given. They are used to demonstrate target engagement, pathway inhibition, or downstream physiological change.
These markers are common in early-phase drug development, where researchers need evidence that a compound is acting as intended. They can help determine dose, timing, and mechanism.
2.5 Susceptibility and risk biomarkers
Susceptibility and risk biomarkers indicate an increased likelihood of developing a disease or condition in the future. They do not necessarily mean that illness is present, but they may reveal a predisposition due to genetics, exposure, or underlying biology.
These biomarkers are important in prevention and screening. When combined with clinical history and other data, they can help identify individuals who may benefit from closer observation or early intervention.
2.6 Monitoring biomarkers
Monitoring biomarkers are used to track the status of a disease or the effect of treatment over time. They can show whether a condition is stable, improving, or worsening, and they are often measured repeatedly.
Because they allow serial assessment, these biomarkers are useful in chronic disease management, treatment adjustment, and follow-up after therapy. They are often chosen for practicality, consistency, and sensitivity to change.
2.7 Surrogate endpoints
Surrogate endpoints are biomarkers intended to substitute for a clinical outcome, such as survival, symptom relief, or functional improvement. They are used in research and regulatory settings when direct outcome measurement would require too much time or be impractical.
A surrogate endpoint must be strongly linked to the true clinical outcome to be reliable. If the relationship is weak, the marker may not accurately reflect meaningful benefit or harm.
3 Biological sources and measurement
Biomarkers can be obtained from many biological sources, and the choice of source depends on the question being asked. Some are simple and inexpensive to measure, while others require specialized instrumentation or image analysis. The value of the measurement depends not only on what is detected, but also on how consistently it can be measured.
3.1 Blood-based biomarkers
Blood is one of the most common sources for biomarkers because it is relatively accessible and can reflect systemic changes. Measurements may include hormones, enzymes, lipids, inflammatory proteins, cells, or circulating nucleic acids.
Blood-based biomarkers are used in many fields of medicine, from routine screening to complex disease monitoring. They are especially useful when disease processes affect multiple organs or release detectable substances into circulation.
3.2 Urine-based biomarkers
Urine biomarkers are useful because urine can be collected noninvasively and often contains compounds filtered or secreted by the kidneys. These markers may reflect kidney function, infection, metabolism, or the presence of substances excreted from the body.
Urine testing is widely used for screening and monitoring. It is particularly valuable when repeated sampling is needed or when blood collection is impractical.
3.3 Tissue biomarkers
Tissue biomarkers are measured in biopsied or surgically removed material. They can provide detailed information about local cellular structure, protein expression, genetic alterations, and disease architecture.
Because tissue reflects the affected site more directly than blood or urine, it can be highly informative in cancer and inflammatory disorders. However, tissue sampling is more invasive and may not always be feasible.
3.4 Imaging biomarkers
Imaging biomarkers are features identified through radiology, microscopy, or other visual technologies. They may include lesion size, tissue density, signal intensity, uptake patterns, or structural changes visible on scans.
These biomarkers are useful because they can assess anatomy and function without requiring tissue removal. They are often applied in diagnosis, staging, and longitudinal monitoring.
3.5 Molecular and genetic biomarkers
Molecular and genetic biomarkers capture changes at the level of DNA, RNA, proteins, or related molecules. They are central to modern precision medicine because they can reveal mechanisms that are not apparent from standard clinical observation.
These markers may identify inherited traits, acquired mutations, expression patterns, or biochemical pathways. Their interpretation often requires specialized analytical methods.
3.5.1 DNA markers
DNA markers include inherited variants, mutations, copy number changes, and other alterations in genetic material. They may be used to identify disease predisposition, confirm a molecular diagnosis, or guide treatment choice.
Because DNA is relatively stable, these markers are often suitable for robust testing. They are widely used in oncology, rare disease diagnosis, and inherited condition assessment.
3.5.2 RNA markers
RNA markers reflect gene expression and can show which genes are active in a cell or tissue at a given time. They are generally more dynamic than DNA markers and may change with disease state or treatment.
RNA-based measurements are useful for understanding regulatory activity, pathway activation, and short-term biological responses. They often require careful handling because RNA can degrade easily.
3.5.3 Protein markers
Protein markers are among the most familiar biomarkers in clinical practice. They may include enzymes, receptors, antibodies, or other proteins released into blood, tissue, or fluids.
Because proteins often carry out biological functions directly, they are useful indicators of injury, inflammation, immune activity, and cellular behavior. Many established clinical tests are protein-based assays.
3.6 Metabolic and biochemical markers
Metabolic and biochemical markers measure small molecules or chemical products of cellular activity. Examples include glucose, lipids, electrolytes, metabolites, and enzymes.
These markers are often used in routine clinical chemistry because they provide rapid insight into physiology and organ function. They can also reflect broader disturbances in energy use, nutrition, or disease metabolism.
4 Discovery and development
Biomarker discovery and development involve identifying candidate markers, testing whether they are measurable and reliable, and determining whether they are useful in real-world settings. This process is methodical and often lengthy because a biomarker must be both scientifically valid and clinically meaningful.
4.1 Biomarker discovery methods
Discovery begins by identifying patterns associated with disease, treatment response, or biological change. Candidates may arise from laboratory experiments, observational studies, or analysis of clinical data.
4.1.1 Omics technologies
Omics technologies include genomics, transcriptomics, proteomics, metabolomics, and related large-scale approaches. They allow researchers to examine thousands of molecules at once and identify patterns linked to specific states or outcomes.
These methods are powerful for generating hypotheses, discovering new pathways, and finding combinations of markers that may be more informative than a single measurement.
4.1.2 High-throughput screening
High-throughput screening tests many molecules, samples, or conditions in a rapid and automated way. It is used to detect candidate biomarkers or to assess how biological systems respond to drugs and other interventions.
This approach is efficient but often produces many preliminary findings that require later confirmation. It is therefore an early step rather than a final proof of utility.
4.1.3 Bioinformatics analysis
Bioinformatics analysis applies computational methods to large biological datasets. It helps identify patterns, reduce noise, and connect biomarker candidates with pathways, clinical traits, or outcomes.
Because modern datasets are often complex, bioinformatics is essential for distinguishing meaningful signals from random variation. It also supports model building and integrative interpretation.
4.2 Validation process
Validation determines whether a biomarker is accurate, reliable, and useful. A candidate marker may look promising in discovery studies but still fail when tested in broader populations or real clinical settings.
4.2.1 Analytical validation
Analytical validation shows that the test measures what it claims to measure with acceptable precision, accuracy, and reliability. This includes assessing detection limits, reproducibility, and resistance to technical error.
Without analytical validity, a biomarker cannot be trusted, regardless of its biological interest. This step establishes the technical foundation for later clinical use.
4.2.2 Clinical validation
Clinical validation demonstrates that the biomarker is associated with the condition or outcome of interest. It answers whether the marker actually reflects the biological or clinical state it is supposed to indicate.
This stage usually requires studies in independent populations. A marker may be analytically sound yet clinically weak if the association is inconsistent or too small to be useful.
4.2.3 Clinical utility
Clinical utility refers to whether using the biomarker improves decisions or outcomes. A test may be valid but still add little value if it does not change management or benefit patients.
Clinical utility is often the most difficult standard to prove because it requires evidence that the marker leads to better care, more efficient treatment, or improved prediction in practice.
4.3 Reproducibility and standardization
Reproducibility means that a biomarker can be measured consistently across time, laboratories, instruments, and populations. Standardization supports this by using common protocols, calibration methods, and reporting conventions.
Lack of standardization can lead to conflicting results and hinder comparison across studies. For that reason, many biomarker programs emphasize reference materials, quality assurance, and harmonized procedures.
5 Applications in medicine
Biomarkers are widely used in clinical medicine because they can support earlier detection, better classification, and more precise treatment. Their usefulness depends on the condition, the quality of the test, and the way the result is interpreted in context.
5.1 Disease detection and screening
Biomarkers can help identify disease before symptoms appear or confirm suspicion when clinical findings are unclear. Screening applications rely on markers that are sufficiently sensitive and practical for use in larger populations.
In some settings, early detection can lead to timely intervention and better outcomes. In others, the main value is reducing uncertainty and prompting closer follow-up.
5.2 Disease staging and classification
Biomarkers can help determine how advanced a disease is or classify it into biologically meaningful subtypes. This is especially important when disorders that appear similar clinically have different molecular features or prognoses.
Classification based on biomarkers can improve diagnostic precision and support decisions about intensity of treatment. It is widely used in oncology and certain inherited or inflammatory conditions.
5.3 Treatment selection
Biomarkers can guide the choice of therapy by identifying patients more likely to benefit from one treatment than another. This reduces trial-and-error prescribing and may improve the balance between benefit and adverse effects.
Treatment selection biomarkers are central to targeted therapy and personalized medicine. They are often paired with companion diagnostics in clinical practice.
5.4 Monitoring disease activity
Repeated biomarker measurement can show whether disease activity is increasing, decreasing, or stable. This is useful for chronic illnesses, relapse detection, and assessment of therapeutic response.
Monitoring biomarkers may allow earlier intervention than waiting for symptoms to worsen. They can also help clinicians adjust treatment more objectively.
5.5 Assessing prognosis
Prognostic biomarkers help estimate the future course of disease, including the likelihood of recovery, recurrence, progression, or complications. They are often combined with age, clinical findings, and other tests to refine prediction.
Their main role is to improve risk assessment and support planning. In some settings, they also influence decisions about how aggressive treatment should be.
5.6 Personalized medicine
Personalized medicine uses biomarker information to tailor prevention, diagnosis, and treatment to the individual. Rather than relying only on average responses in large groups, it considers biological differences among patients.
Biomarkers are a cornerstone of this approach because they can reveal variation in disease mechanism, drug metabolism, and treatment sensitivity. This makes care more targeted and potentially more efficient.
6 Applications in research
In research, biomarkers provide measurable endpoints that help test hypotheses, compare groups, and assess biological mechanisms. They are used across laboratory science, clinical studies, public health, and therapeutic development.
6.1 Basic biological research
Biomarkers are used in basic research to explore how cells, tissues, and organisms function. They can indicate pathway activity, cellular stress, differentiation, or response to experimental manipulation.
These measurements help scientists connect molecular mechanisms with observable outcomes. They are particularly important when direct clinical effects are not yet measurable.
6.2 Clinical trials
Clinical trials frequently use biomarkers to define study populations, track response, or serve as endpoints. They may help identify participants with a specific biological subtype or measure whether an intervention affects its intended target.
Biomarkers can make trials more efficient by enriching for likely responders or by providing early evidence of effect. They also support dose-finding and mechanism studies.
6.3 Population studies
Population studies use biomarkers to examine patterns of exposure, disease risk, and health outcomes in groups of people. These studies may investigate nutrition, environmental exposure, inflammation, or genetic susceptibility.
Because biomarker data are quantitative, they can strengthen epidemiologic analysis and reduce reliance on self-report alone. They also help identify trends that are not obvious from clinical records.
6.4 Drug development
Drug development relies heavily on biomarkers to select targets, assess pharmacology, and monitor safety or efficacy. Biomarkers can show whether a compound reaches its target, affects the intended pathway, or produces unexpected biological effects.
They are valuable at multiple stages, from early discovery to late-phase trials. In successful programs, biomarkers shorten development time and improve the chance of demonstrating benefit.
7 Interpretation and limitations
Biomarkers are useful only when interpreted carefully. A result may be informative in one setting but misleading in another, especially if the test is affected by population differences, technical variation, or other biological factors.
7.1 Sensitivity and specificity
Sensitivity is the ability of a biomarker to identify people who truly have the condition, while specificity is the ability to exclude those who do not. A highly sensitive marker reduces missed cases, whereas a highly specific marker reduces unnecessary positive results.
These properties often involve trade-offs. The ideal balance depends on whether the test is used for screening, diagnosis, or confirmation.
7.2 Predictive value
Predictive value describes the chance that a positive or negative result is correct in a particular population. Unlike sensitivity and specificity, it depends strongly on how common the condition is in the group being tested.
A biomarker can perform well in one setting and poorly in another if disease prevalence changes. This makes context essential for interpretation.
7.3 False positives and false negatives
False positives occur when a test suggests a condition is present when it is not, while false negatives occur when disease or risk is missed. Both can lead to inappropriate decisions, delayed care, or unnecessary anxiety.
The likelihood of such errors depends on assay quality, cutoff values, and biological variation. Careful validation and confirmatory testing help reduce these problems.
7.4 Confounding factors
Confounding factors are variables that can affect biomarker levels independently of the condition being studied. These may include age, medication use, diet, exercise, infection, or other illnesses.
If confounders are not accounted for, a biomarker may appear more or less informative than it really is. Proper study design and statistical adjustment are therefore essential.
7.5 Biological variability
Biological variability refers to natural changes in marker levels within and between individuals over time. Some markers fluctuate with circadian rhythm, stress, hydration, or short-term physiological changes.
This variability can complicate interpretation, especially when values are near decision thresholds. Repeated measurements and standardized collection conditions can improve reliability.
7.6 Ethical and practical considerations
Biomarker testing can raise issues related to privacy, informed consent, incidental findings, and access to care. Some tests may reveal information about future disease risk or hereditary traits that has implications beyond the immediate clinical question.
Practical concerns also matter, including cost, sample collection burden, and availability of specialized laboratories. A biomarker is most useful when it is not only informative, but also feasible and appropriate for the intended setting.
8 Regulatory and quality issues
Because biomarkers may influence diagnosis, treatment, and trial outcomes, they are subject to quality expectations and regulatory oversight. Standards help ensure that results are trustworthy and that their intended use is clear.
8.1 Standards and guidelines
Professional and scientific organizations issue standards for biomarker development, testing, and interpretation. These guidelines address study design, assay performance, reporting, and evidence thresholds.
Such standards help align research and clinical practice. They also make it easier to compare findings across institutions and over time.
8.2 Laboratory quality control
Laboratory quality control ensures that biomarker assays produce accurate and consistent results. It includes calibration, internal controls, proficiency testing, and routine monitoring for drift or error.
Strong quality systems are necessary because small technical differences can alter interpretation. This is especially important for low-abundance markers and tests used near clinical cutoffs.
8.3 Regulatory approval
Some biomarkers, especially those used for diagnosis or treatment selection, require formal regulatory review before clinical use. Approval generally depends on evidence of analytical validity, clinical validity, and, in some cases, clinical utility.
The regulatory process helps protect patients from unreliable or misleading tests. It also clarifies the approved purpose of the biomarker and the population in which it should be used.
8.4 Reporting and interpretation standards
Clear reporting standards help ensure that biomarker results are presented with the information needed for proper interpretation. Reports may need to include assay method, reference range, cutoff value, units, and relevant limitations.
Interpretation should consider the clinical setting rather than the number alone. Well-structured reporting reduces ambiguity and supports safer decision-making.